ankylosing spondylitis Bechterew's disease
Conditions
Interventions
The tapering schedule consists of doubling the dosage interval of the TNFi.
Patients that develop a flare will return to their original treatment schedule.
In addition, a whole body dual-energy X-ra
Sponsors
Vrije Universiteit Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - 18 years or older - Diagnosis of ankylosing spondylitis (radiographic axial spondyloarthritis) according to the 1984 modified New York criteria - Use of a TNF-alpha blocker, stable dose during the last 6 months. - At least 6 months of low disease activity in the 6 months prior to study entrance. - Low disease activity at study entrance.
Exclusion criteria
Exclusion criteria: - Planned reasons for treatment discontinuation - Unable to understand the study aims and methods.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The number of patients (percentage men / women) that develop a flare within 1 year after tapering will be the primary outcome measure. | — |
Secondary
| Measure | Time frame |
|---|---|
| Patient- and disease characteristics, anthropometric measures, fat mass and * distribution, physical performance parameters, quality of life and cardiovascular risk profile will be collected as secondary outcomes. In future, pharmacokinetic/ -dynamic measures and changes in the coagulation profile will be evaluated from the stored samples (future study protocols). | — |
Countries
Netherlands
Outcome results
None listed